Some screening assays have been designed to find NRF2 activators [128,210] or modifying known NRF2 activators, such as sulforaphane [211], flavonoids [212], or chalcones [213], among others, to provide therapeutic effects in cellular models of PD [214,215]. Here, NFE2L2 is linked to Parkinson disease.